Kelly Johnson-Wood

Title: The Innovative Contributions of Kelly Johnson-Wood

Introduction

Kelly Johnson-Wood is a prominent inventor based in Scotts Valley, California. She has made significant contributions to the field of neurobiology, particularly in the context of Alzheimer's disease. Her work focuses on the development of novel therapeutic approaches that target amyloid precursor protein (APP).

Latest Patents

Johnson-Wood holds a patent for "Neuroactive fragments of APP." This patent describes innovative neuroactive fragments derived from human amyloid precursor protein. The fragments include sequences from the Aβ region of APP and extend upstream. They are soluble in aqueous solutions, with most bands being approximately 10 kDa and above, which do not correspond to the expected molecular weight of a dimer or trimer. These fragments can be utilized as immunogens in immunotherapy methods aimed at treating Alzheimer's and other amyloidogenic diseases characterized by Aβ deposits in the brain. Additionally, antibodies targeting the fragment upstream from APP or the interface between Aβ and the upstream sequence can be employed in therapeutic methods. The fragments also serve as useful markers for diagnosing or prognosing diseases or for screening agents.

Career Highlights

Kelly Johnson-Wood is currently associated with Janssen Alzheimer Immunotherapy, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of neuroactive fragments and their potential applications in treating neurodegenerative diseases.

Collaborations

Some of her notable coworkers include Peter Andrew Seubert and Thierry Bussiere, who collaborate with her in various research initiatives.

Conclusion

Kelly Johnson-Wood's innovative work in the field of neurobiology and her patent on neuroactive fragments of APP highlight her significant contributions to Alzheimer's research. Her efforts pave the way for potential therapeutic advancements in treating neurodegenerative diseases.